news
FDA approves Vyzulta for open-angle glaucoma and ocular hypertension
The FDA has approved a New Drug Application for Vyzulta for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension....
List view / Grid view
Valeant Pharmaceuticals International Inc.
news
US ophthalmic drugs market set to pass $34bn by 2025
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
news
Valeant announces sale of iNova Pharmaceuticals for $930 million
Valeant Pharmaceuticals has entered into an agreement to sell its iNova Pharmaceuticals business for $930 million in cash.
news
FDA approves new psoriasis drug that induced suicide in trial
17 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has approved Valeant’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or…
news
AstraZeneca licenses skin disease drugs to LEO Pharma
1 July 2016 | By Victoria White, Digital Content Producer
AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.
news
Valeant Pharmaceuticals probed on drug pricing
15 October 2015 | By Victoria White
Valeant has also revealed that it has responded to a letter from US Senator Claire McCaskill concerning the price of Nitropress and Isuprel...
news
FDA grants HAE drug Ruconest 12-years of exclusivity
8 October 2015 | By Victoria White
The exclusivity ensures that the FDA will not approve any applications for biosimilars of the drug before July 2026...
news
Valeant to acquire Sprout for $1 billion
20 August 2015 | By Victoria White
Valeant has entered into a definitive agreement to acquire Sprout, makers of female libido drug Addyi, for approximately $1 billion...
news
Janssen Pharmaceuticals, Inc. announces definitive agreement to divest Ortho Dermatologics Division
15 July 2011 | By Janssen Pharmaceuticals Inc
Janssen Pharmaceuticals, Inc. announced a definitive agreement to divest the assets of its Ortho Dermatologics division...
news
Sanofi Divests Dermik Dermatology Unit to Valeant
11 July 2011 | By Sanofi
Sanofi announced the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc...
news
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)
13 June 2011 | By GlaxoSmithKline
GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced that the FDA has approved Potiga™ (ezogabine) Tablets...
news
Valeant Pharmaceuticals to Acquire PharmaSwiss S.A.
1 February 2011 | By Valeant Pharmaceuticals International Inc.
Valeant Pharmaceuticals International, Inc. and PharmaSwiss S.A. announced today that they have signed a binding agreement for Valeant to acquire PharmaSwiss...
